Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Inova Health Care Services
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06023199CT.gov Assessing Physical Function in Sickle Cell Patients Taking Voxelotor | — | Active Not Recruiting | — | — | — |
NCT05228821CT.gov Voxelotor Brain Oxygenation and Neurocognitive Study | — | Withdrawn | — | — | — |
NCT05981365CT.gov Voxelotor CYP and Transporter Cocktail Interaction Study | — | Completed | — | — | — |
NCT05199766CT.gov Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor | — | Unknown | — | — | — |
NCT05228834CT.gov Voxelotor Neurocognitive Function Study | — | Terminated | — | — | — |
NCT05561140CT.gov Resolution of Sickle Cell Leg Ulcers With Voxelotor | — | Terminated | — | — | — |
NCT05018728CT.gov The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia | — | Terminated | — | — | — |
NCT04930445CT.gov Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD | — | Terminated | — | — | — |
NCT04930328CT.gov Retrospective Real World Oxbryta® Data Collection and Analysis Study | — | Completed | — | — | — |
NCT04335721CT.gov A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease | — | Terminated | — | — | — |
Show 15 more trialsShow fewer
NCT04400487CT.gov Actigraphy Improvement With Voxelotor (ActIVe) Study | — | Completed | — | — | — |
NCT04218084CT.gov Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease | — | Terminated | — | — | — |
NCT04581356CT.gov Voxelotor Sickle Cell Exercise Study | — | Completed | — | — | — |
NCT04247594CT.gov Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD | — | Terminated | — | — | — |
NCT04188509CT.gov Open-Label Extension of Voxelotor | — | Terminated | — | — | — |
NCT03573882CT.gov Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 | — | Terminated | — | — | — |
NCT03036813CT.gov Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) | — | Completed | — | — | — |
NCT03041909CT.gov An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001 | — | Completed | — | — | — |
NCT02850406CT.gov Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease | — | Terminated | — | — | — |
NCT02567695CT.gov A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects | — | Completed | — | — | — |
NCT02567682CT.gov Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects | — | Completed | — | — | — |
NCT02497924CT.gov A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects | — | Completed | — | — | — |
NCT02285088CT.gov A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease | — | Completed | — | — | — |
NCT03943615CT.gov Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options | — | No Longer Available | — | — | — |
NCT04724421CT.gov Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Voxelotor (this asset) | Inova Health Care Services | Approved | B · 57 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| Fentanyl | University College Dublin | P4 | BB |
| ARG | Tanta University | P3 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Voxelotor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ulcer Of Lower Limbs | — | P3 | CCC · 48 |
| Idiopathic Pulmonary Fibrosis | — | P2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Voxelotor in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/voxelotor-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →